The Life Sciences team advised Enterome on its global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited ("Takeda"). The agreement covers Enterome's lead investigational drug candidate EB8018 in patients with Crohn's disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.
Under the terms of the agreement, Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with EB8018. In addition, Enterome and Takeda will co-develop EB8018 and, if approved, the product will be co-promoted in the US under a profit/cost sharing structure. Takeda will receive an exclusive license to commercialize EB8018 outside of the US, and Enterome will be eligible to receive royalties on net sales generated in these territories.
Enterome is a clinical-stage company pioneering the development of novel pharmaceuticals based on its leading knowledge of the interaction between the immune system and the gut microbiome.
The Goodwin team was led by partner Jonathan Schur and included partners Theresa Kavanaugh, Julie Tibbets and Paul Jin, as well as associates Emily Beman and Mayan Katz. Enterome was also advised by Luc Barny of the Strasbourg bar.
For additional information on the agreement, please read the press release.